Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001415889-25-012489·GV 2019, L.P.
Schedule 13G ownership disclosure
Maze Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 578784100
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- GV 2019, L.P.
Shares: 1,807,907.00 · Class: 4.1%
- GV 2019 GP, L.P.
Shares: 1,807,907.00 · Class: 4.1%
- GV 2019 GP, L.L.C.
Shares: 1,807,907.00 · Class: 4.1%
- GV 2023, L.P.
Shares: 604,564.00 · Class: 1.4%
- GV 2023 GP, L.P.
Shares: 604,564.00 · Class: 1.4%
- GV 2023 GP, L.L.C.
Shares: 604,564.00 · Class: 1.4%
- Alphabet Holdings LLC
Shares: 2,412,471.00 · Class: 5.5%
- XXVI Holdings Inc.
Shares: 2,412,471.00 · Class: 5.5%
- Alphabet Inc.
Shares: 2,412,471.00 · Class: 5.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-012489
- Form type
- SCHEDULE 13G
- Filer
- GV 2019, L.P.
- CIK
- CIK 1845041
- Filed
- May 09, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership